These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
207 related articles for article (PubMed ID: 32361951)
1. Once-yearly zoledronic acid and change in abdominal aortic calcification over 3 years in postmenopausal women with osteoporosis: results from the HORIZON Pivotal Fracture Trial. Cai G; Keen HI; Host LV; Aitken D; Laslett LL; Winzenberg T; Wluka AE; Black D; Jones G Osteoporos Int; 2020 Sep; 31(9):1741-1747. PubMed ID: 32361951 [TBL] [Abstract][Full Text] [Related]
2. Relationship of changes in total hip bone mineral density to vertebral and nonvertebral fracture risk in women with postmenopausal osteoporosis treated with once-yearly zoledronic acid 5 mg: the HORIZON-Pivotal Fracture Trial (PFT). Jacques RM; Boonen S; Cosman F; Reid IR; Bauer DC; Black DM; Eastell R J Bone Miner Res; 2012 Aug; 27(8):1627-34. PubMed ID: 22532515 [TBL] [Abstract][Full Text] [Related]
3. Longitudinal changes in bone mineral density and trabecular bone score following yearly zoledronic acid infusion in postmenopausal osteoporosis-a retrospective-prospective study from southern India. Sooragonda B; Cherian KE; Jebasingh FK; Dasgupta R; Asha HS; Kapoor N; Thomas N; Paul TV Arch Osteoporos; 2019 Jul; 14(1):79. PubMed ID: 31321603 [TBL] [Abstract][Full Text] [Related]
7. The effects of intravenous zoledronic acid in Chinese women with postmenopausal osteoporosis. Hwang JS; Chin LS; Chen JF; Yang TS; Chen PQ; Tsai KS; Leung PC J Bone Miner Metab; 2011 May; 29(3):328-33. PubMed ID: 20922438 [TBL] [Abstract][Full Text] [Related]
8. Review of the cardiovascular safety of zoledronic acid and other bisphosphonates for the treatment of osteoporosis. John Camm A Clin Ther; 2010 Mar; 32(3):426-36. PubMed ID: 20399982 [TBL] [Abstract][Full Text] [Related]
9. Effect of once-yearly zoledronic acid five milligrams on fracture risk and change in femoral neck bone mineral density. Eastell R; Black DM; Boonen S; Adami S; Felsenberg D; Lippuner K; Cummings SR; Delmas PD; Palermo L; Mesenbrink P; Cauley JA; J Clin Endocrinol Metab; 2009 Sep; 94(9):3215-25. PubMed ID: 19567517 [TBL] [Abstract][Full Text] [Related]
10. Effect of bisphosphonate use on risk of postmenopausal breast cancer: results from the randomized clinical trials of alendronate and zoledronic acid. Hue TF; Cummings SR; Cauley JA; Bauer DC; Ensrud KE; Barrett-Connor E; Black DM JAMA Intern Med; 2014 Oct; 174(10):1550-7. PubMed ID: 25111880 [TBL] [Abstract][Full Text] [Related]
11. Effects of intravenous zoledronic acid once yearly on bone remodeling and bone structure. Recker RR; Delmas PD; Halse J; Reid IR; Boonen S; García-Hernandez PA; Supronik J; Lewiecki EM; Ochoa L; Miller P; Hu H; Mesenbrink P; Hartl F; Gasser J; Eriksen EF J Bone Miner Res; 2008 Jan; 23(1):6-16. PubMed ID: 17892374 [TBL] [Abstract][Full Text] [Related]
12. Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension study. McClung MR; O'Donoghue ML; Papapoulos SE; Bone H; Langdahl B; Saag KG; Reid IR; Kiel DP; Cavallari I; Bonaca MP; Wiviott SD; de Villiers T; Ling X; Lippuner K; Nakamura T; Reginster JY; Rodriguez-Portales JA; Roux C; Zanchetta J; Zerbini CAF; Park JG; Im K; Cange A; Grip LT; Heyden N; DaSilva C; Cohn D; Massaad R; Scott BB; Verbruggen N; Gurner D; Miller DL; Blair ML; Polis AB; Stoch SA; Santora A; Lombardi A; Leung AT; Kaufman KD; Sabatine MS; Lancet Diabetes Endocrinol; 2019 Dec; 7(12):899-911. PubMed ID: 31676222 [TBL] [Abstract][Full Text] [Related]
13. Effects of intravenous zoledronic acid plus subcutaneous teriparatide [rhPTH(1-34)] in postmenopausal osteoporosis. Cosman F; Eriksen EF; Recknor C; Miller PD; Guañabens N; Kasperk C; Papanastasiou P; Readie A; Rao H; Gasser JA; Bucci-Rechtweg C; Boonen S J Bone Miner Res; 2011 Mar; 26(3):503-11. PubMed ID: 20814967 [TBL] [Abstract][Full Text] [Related]
14. Zoledronic acid for the prevention of bone loss in postmenopausal women with low bone mass: a randomized controlled trial. McClung M; Miller P; Recknor C; Mesenbrink P; Bucci-Rechtweg C; Benhamou CL Obstet Gynecol; 2009 Nov; 114(5):999-1007. PubMed ID: 20168099 [TBL] [Abstract][Full Text] [Related]
15. Intravenous Zoledronic Acid 5 mg on Bone Turnover Markers and Bone Mineral Density in East China Subjects with Newly Diagnosed Osteoporosis: A 24-month Clinical Study. Liang BC; Shi ZY; Wang B; Wu P; Kong LC; Yao JL; Li CW; Shi XL Orthop Surg; 2017 Feb; 9(1):103-109. PubMed ID: 28276638 [TBL] [Abstract][Full Text] [Related]
16. Zoledronic acid increases bone mineral density and improves health-related quality of life over two years of treatment in Chinese women with postmenopausal osteoporosis. Huang S; Lin H; Zhu X; Chen X; Fan L; Liu C Endokrynol Pol; 2014; 65(2):96-104. PubMed ID: 24802732 [TBL] [Abstract][Full Text] [Related]
17. Treatment with zoledronic acid subsequent to odanacatib prevents bone loss in postmenopausal women with osteoporosis. Koldkjær Sølling AS; Harsløf T; Langdahl B Osteoporos Int; 2019 May; 30(5):995-1002. PubMed ID: 30656367 [TBL] [Abstract][Full Text] [Related]
18. Site-specific differential effects of once-yearly zoledronic acid on the hip assessed with quantitative computed tomography: results from the HORIZON Pivotal Fracture Trial. Yang L; Sycheva AV; Black DM; Eastell R Osteoporos Int; 2013 Jan; 24(1):329-38. PubMed ID: 23128664 [TBL] [Abstract][Full Text] [Related]
19. Efficacy and Safety of Zoledronic Acid for Treatment of Postmenopausal Osteoporosis: A Meta-Analysis of Randomized Controlled Trials. Wang C Am J Ther; 2017; 24(5):e544-e552. PubMed ID: 26938765 [TBL] [Abstract][Full Text] [Related]
20. Zoledronic acid: a review of its use in the treatment of osteoporosis. Deeks ED; Perry CM Drugs Aging; 2008; 25(11):963-86. PubMed ID: 18947264 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]